(NASDAQ: ADVM) Adverum Biotechnologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.
Adverum Biotechnologies's earnings in 2025 is -$130,927,000.On average, 6 Wall Street analysts forecast ADVM's earnings for 2025 to be -$114,758,003, with the lowest ADVM earnings forecast at -$146,233,780, and the highest ADVM earnings forecast at -$73,743,606. On average, 2 Wall Street analysts forecast ADVM's earnings for 2026 to be -$132,654,929, with the lowest ADVM earnings forecast at -$136,833,037, and the highest ADVM earnings forecast at -$128,476,821.
In 2027, ADVM is forecast to generate -$149,994,077 in earnings, with the lowest earnings forecast at -$149,994,077 and the highest earnings forecast at -$149,994,077.